A Study of Repetitive Transcranial Magnetic Stimulation as a Treatment for Depression Added to Standard Care


About this study

The purpose of this study is to systematically investigate the use of repetitive transcranial magnetic stimulation (rTMS) as an added treatment for patients who have depression that is not decreasing with standard care.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • Depressive symptoms have not remitted during participation in the "Pharmacokinetics and Pharmacodynamics of Citalopram and Escitalopram" study or the "Pharmacokinetics and Pharmacodynamics of Duloxetine" study
  • Must be able to continue to take same dose of duloxetine through the course of the study

Exclusion Criteria

  • A history of failure to respond to Electroconvulsive Therapy (ECT)
  • Any metal in the head (except in mouth)
  • Implanted medication pump or cardiac pacemaker
  • Has had prior brain surgery
  • Has unprovoked seizure disorder or family history of treatment resistant epilepsy
  • Pregnancy
  • Psychiatric hospitalization within the past two weeks
  • Suicide attempt with hospitalization within past three months

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

David Mrazek, M.D.

Closed for enrollment

More information


Publications are currently not available

Mayo Clinic Footer